Skip to content

Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass

Obesity | Diabetes | Magnetic Resonance Imaging | MRI | Muscle

Semaglutide is a medication widely prescribed to treat type 2 diabetes and obesity by lowering blood sugar and helping with weight loss. However, recent studies suggest that a significant portion of this weight loss may come from muscle mass, including heart muscle, which plays a crucial role in strength, movement, and overall health. This study aims to use advanced MRI scans to track changes in both muscle and fat in the body and heart over a 12-month period in individuals starting semaglutide. By doing so, we hope to gain a clearer understanding of how semaglutide affects muscle health and function. Our goal is to ensure the medication supports long-term well-being, particularly for people who may be at higher risk of muscle loss.

null

Participation Requirements

  • Sex:

    Any

  • Eligible Ages:

    18 to 80

Participation Criteria

Inclusion Criteria:
- Adults 18-80 years of age
- Starting semaglutide for type 2 diabetes or weight loss (body mass index ≥27.5kg/m2)
- Able to safely undergo an MRI scan (including meeting the physical requirements for MRI equipment)
Exclusion Criteria:
- Current use of semaglutide for more than 2 weeks
- Major recent heart issues or other severe health conditions
- Concerns related to MRI use (e.g. metal implants, severe claustrophobia)

Study Location

University of Alberta
University of Alberta
Edmonton, Alberta
Canada

Contact Study Team

Primary Contact

Krista Jong

[email protected]
null
Study Sponsored By
University of Alberta
Participants Required
More Information
Study ID: Pro00153724